Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Pliaglis, Synera
Synonyms :
lidocaine/tetracaine
Class :
Topical Anesthestics
Dosage Forms & StrengthsÂ
lidocaine/tetracaine Â
Topical CreamÂ
7%/7% lidocaine/tetracaine (Pliaglis)Â Â Â
Transdermal PatchÂ
70mg/70mg lidocaine/tetracaine (Synera)Â Â
Â
Indicated for Local Dermal Analgesia:
Superficial dermatologic treatments
Patch- Apply the patch to healthy skin for 30 minutes before the treatment
IV cannulation or venipuncture
Patch- Before the treatment, apply the patch to healthy skin for 30 minutes
Topical Cream
Indicated for topical local analgesia during superficial dermatological treatments on adults with undamaged skin
Apply to healthy skin 20 to 30 minutes before superficial dermatological operations
Apply at least 60 minutes before laser tattoo removal or equivalent treatments
Dosage Forms & Strengths Â
Transdermal PatchÂ
70mg/70mg lidocaine/tetracaine (Synera)Â Â
Local Dermal Analgesia
Superficial dermatologic treatments
<3 years: Safety and Efficacy not established
>3 years: Patch- Before the treatment, apply the patch to healthy skin for 30 minutes
IV cannulation or Venipuncture
<3 years: Safety and Efficacy not established
>3 years: Patch- Before the treatment, apply the patch to healthy skin for 30 minutes
Refer adult dosingÂ
may increase the adverse effect of Antiarrhythmic Agents
may increase the adverse effect of Antiarrhythmic Agents
may increase the adverse effect of Antiarrhythmic Agents
may increase the adverse effect of Antiarrhythmic Agents
may increase the adverse effect of Antiarrhythmic Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the adverse effect of Methemoglobinemia Associated Agents
may increases the adverse effect of Local Anesthetics
may increases the adverse effect of Local Anesthetics
may increases the adverse effect of Local Anesthetics
may increases the adverse effect of Local Anesthetics
may increases the adverse effect of Local Anesthetics
may increase the adverse effect of Methemoglobinemia Associated Agents
Actions and Spectrum:Â
Frequency definedÂ
>10%Â
Localized blanching (12%)Â
Localized erythema (71%)Â
Localized edema (12%)Â Â
1-10%Â
Other reactions at the site of the application Â
<1%Â
Application site reactionsÂ
DizzinessÂ
PainÂ
Contact dermatitisÂ
Skin discolorationÂ
Allergic reactionÂ
ParesthesiaÂ
Vesiculobullous rashÂ
RashÂ
PruritusÂ
HeadacheÂ
N/VÂ
InfectionÂ
SomnolenceÂ
BlisterÂ
UrticariaÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
lidocaine and tetracaine can be absorbed systemically when administered topically, but the degree of absorption positively correlates with the amount of drug applied and the duration of exposure.Â
lidocaine has a peak plasma concentration of 148-641 ng/mL, while the peak plasma concentration of tetracaine is not well-established. Â
DistributionÂ
The volume of distribution (Vd) of lidocaine after intravenous administration is 0.8-1.3 L/kg.Â
lidocaine is highly protein-bound, with 75% bound to plasma proteins.Â
The Vd and protein binding of tetracaine need to be well-established.Â
MetabolismÂ
It is unclear if lidocaine and tetracaine are metabolized in the skin.Â
lidocaine is metabolized in the liver, while plasma esterases metabolize tetracaine.Â
Both lidocaine and tetracaine are metabolized into ester- and amide-type local anesthetics. Â
Elimination and ExcretionÂ
The half-life of lidocaine after intravenous administration is 1.8 hours.Â
lidocaine is primarily excreted in the urine (98%) after intravenous administration.Â
The elimination of tetracaine needs to be well-established.Â
Administration:Â
Patient information leafletÂ
Generic Name: lidocaine/tetracaineÂ
Why do we use lidocaine/tetracaine?Â
lidocaine/tetracaine is a combination of two local anesthetics that are used for various purposes, including:Â